Citigroup’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$375M Buy
2,969,159
+668,888
+29% +$88.1M 0.12% 146
2026
Q1
$321M Buy
2,300,271
+524,041
+30% +$73.4M 0.14% 145
2025
Q4
$218M Buy
1,776,230
+332,996
+23% +$40.5M 0.1% 187
2025
Q3
$160M Sell
1,443,234
-797,412
-36% -$90.6M 0.07% 272
2025
Q2
$248M Buy
2,240,646
+191,974
+9% +$20.4M 0.12% 167
2025
Q1
$230M Buy
2,048,672
+354,472
+21% +$36.6M 0.12% 158
2024
Q4
$156M Sell
1,694,200
-658,688
-28% -$59.3M 0.09% 194
2024
Q3
$197M Sell
2,352,888
-126,799
-5% -$9.68M 0.11% 158
2024
Q2
$170M Buy
2,479,687
+1,019,158
+70% +$68M 0.11% 169
2024
Q1
$107M Sell
1,460,529
-248,910
-15% -$19.1M 0.07% 260
2023
Q4
$138M Sell
1,709,439
-270,960
-14% -$21.1M 0.1% 185
2023
Q3
$148M Sell
1,980,399
-90,454
-4% -$6.96M 0.11% 149
2023
Q2
$160M Buy
2,070,853
+157,496
+8% +$12.6M 0.1% 146
2023
Q1
$159M Buy
1,913,357
+68,737
+4% +$5.69M 0.11% 148
2022
Q4
$158M Sell
1,844,620
-84,044
-4% -$6.66M 0.13% 145
2022
Q3
$119M Buy
1,928,664
+166,557
+9% +$10.5M 0.09% 177
2022
Q2
$109M Sell
1,762,107
-439,080
-20% -$27.2M 0.08% 198
2022
Q1
$131M Buy
2,201,187
+42,378
+2% +$2.71M 0.08% 225
2021
Q4
$157M Buy
2,158,809
+709,059
+49% +$48.8M 0.08% 215
2021
Q3
$101M Sell
1,449,750
-211,605
-13% -$14.9M 0.06% 289
2021
Q2
$114M Sell
1,661,355
-178,262
-10% -$11.9M 0.07% 266
2021
Q1
$119M Sell
1,839,617
-637,921
-26% -$41.1M 0.08% 235
2020
Q4
$144M Buy
2,477,538
+271,613
+12% +$16.4M 0.09% 213
2020
Q3
$139M Buy
2,205,925
+450,684
+26% +$31.3M 0.09% 175
2020
Q2
$135M Sell
1,755,241
-22,521
-1% -$1.73M 0.11% 161
2020
Q1
$133M Sell
1,777,762
-4,247
-0.2% -$293K 0.12% 139
2019
Q4
$116M Buy
1,782,009
+518,680
+41% +$33.8M 0.08% 209
2019
Q3
$80.1M Sell
1,263,329
-197,061
-13% -$12.9M 0.06% 294
2019
Q2
$98.7M Sell
1,460,390
-402,543
-22% -$26.5M 0.08% 234
2019
Q1
$121M Buy
1,862,933
+358,356
+24% +$23.8M 0.12% 154
2018
Q4
$94.1M Sell
1,504,577
-126,158
-8% -$8.82M 0.1% 200
2018
Q3
$126M Sell
1,630,735
-94,013
-5% -$7.1M 0.11% 155
2018
Q2
$122M Sell
1,724,748
-269,861
-14% -$19.1M 0.11% 145
2018
Q1
$150M Sell
1,994,609
-45,255
-2% -$3.6M 0.12% 127
2017
Q4
$146M Buy
2,039,864
+683,571
+50% +$51.9M 0.12% 152
2017
Q3
$110M Buy
1,356,293
+443,460
+49% +$33.9M 0.09% 187
2017
Q2
$64.6M Sell
912,833
-1,371,765
-60% -$91.3M 0.06% 270
2017
Q1
$155M Buy
2,284,598
+239,489
+12% +$16.8M 0.14% 91
2016
Q4
$146M Buy
2,045,109
+341,096
+20% +$25.4M 0.13% 120
2016
Q3
$135M Buy
1,704,013
+525,720
+45% +$42.7M 0.13% 128
2016
Q2
$98.3M Sell
1,178,293
-350,959
-23% -$31.1M 0.1% 177
2016
Q1
$140M Sell
1,529,252
-770,105
-33% -$69.4M 0.16% 100
2015
Q4
$233M Buy
2,299,357
+771,725
+51% +$80.3M 0.23% 60
2015
Q3
$150M Buy
1,527,632
+197,464
+15% +$21.9M 0.14% 107
2015
Q2
$156M Sell
1,330,168
-1,215,988
-48% -$133M 0.14% 112
2015
Q1
$250M Buy
2,546,156
+1,090,173
+75% +$111M 0.24% 53
2014
Q4
$137M Buy
1,455,983
+532,421
+58% +$55.1M 0.12% 151
2014
Q3
$98.3M Sell
923,562
-777,916
-46% -$76.2M 0.09% 200
2014
Q2
$141M Sell
1,701,478
-54,555
-3% -$4.25M 0.14% 128
2014
Q1
$124M Buy
1,756,033
+248,690
+16% +$19.5M 0.13% 117
2013
Q4
$113M Buy
1,507,343
+115,564
+8% +$8.05M 0.1% 170
2013
Q3
$87.5M Sell
1,391,779
-19,271
-1% -$1.15M 0.08% 223
2013
Q2
$72.3M Buy
+1,411,050
New +$73.5M 0.07% 215

Other funds holding GILD

Citigroup's GILD Position: Q2 2026 in Review

Citigroup increased its Gilead Sciences (GILD) stake by 29% in Q2 2026, buying an estimated $88.1M and bringing the position to 2,969,159 shares worth $375M. The position accounts for 0.12% of the portfolio, ranked #146.

Citigroup first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. 1,926 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Citigroup held 2,969,159 shares of Gilead Sciences worth $375M as of Q2 2026.
  • Citigroup bought 668,888 Gilead Sciences shares in Q2 2026, an estimated $88.1M.
  • Gilead Sciences made up 0.12% of Citigroup's portfolio in Q2 2026, its #146 holding.
  • Citigroup first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • 1,926 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.